NCT06416397Recruiting
Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy
Source: ClinicalTrials.gov · Last updated 16 Dec 2025
Brief summary (registry, in English)
The main aim of the study is to develop a diagnostic proteomic profile of cholangiocarcinoma using bile samples. The primary endpoint will be the rate of concordant positive diagnoses obtained from bile samples based on proteomic profiling compared with histological reference diagnoses (concomitant cytological sampling and/or final histological sampling).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 1 Feb 2024
- Start date
- 8 Apr 2025
- Primary completion date
- Feb 2026
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06416397
What you commit to
- Study type: Observational
- Planned participants: 200
- From 8 Apr 2025 to the primary completion date, Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant woman
- Patient under legal protection
Who the study is looking for
- Patient 18 years and older
- Patients with bile duct stenosis who require endoscopy with retrograde papillary catheterization or a radiological procedure for diagnostic purposes (histological samples) as part of their management
- Oral consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Bordeaux Coordinator of this site? Confirm its status | Pessac | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.